Open AccessA quantitative method for the determination of bosutinib in human plasma using high‐performance liquid chromatography and ultraviolet detection
Author(s) -
Sumimoto Takahiro,
Nakahara Ryosuke,
Sato Yuhki,
Itoh Hiroki
Publication year - 2018
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.22201
Subject(s) - chromatography , bosutinib , chemistry , high performance liquid chromatography , detection limit , calibration curve , repeatability , ultraviolet , quantitative analysis (chemistry) , extraction (chemistry) , solid phase extraction , analytical chemistry (journal) , materials science , dasatinib , signal transduction , biochemistry , optoelectronics , tyrosine kinase
Background We propose a simple, sensitive, and fast high‐performance liquid chromatography ultraviolet detection ( HPLC ‐ UV ) method for the quantitative determination of bosutinib in human plasma. Methods Plasma samples were processed using an Oasis hydrophilic‐lipophilic balance extraction cartridge (1 mL, 30 mg). Bosutinib and the internal standard imatinib were separated using a mobile phase of 0.5% Na 2 PO 4 H 2 O ( pH 3.5)‐acetonitrile‐methanol (55:25:20, v/v/v) on a CAPCELL PAK C18 MG II reversed‐phase column 250 nm×4.6 nm i.d., at a flow rate of 1.0 mL/min, with ultraviolet detection at 250 nm. Results The calibration curve exhibited linearity over the bosutinib concentration range of 25‐1500 ng/mL at 250 nm, with coefficient of variation for intraday precision of 2.42%, 6.04%, and 1.11% for 100, 250, and 1500 ng/mL, respectively, of bosutinib. The lower limit of detection was 20 ng/mL. The extraction recovery rates for bosutinib ranged from 84.36% to 85.82%. The intra‐ and interday precision was below 8.7%, and the accuracy ranged from −5.95% to 5.85% over the linear range. No notable matrix effects or astaticism were observed. Conclusion The proposed HPLC ‐ UV method was successfully applied as an assay to detect bosutinib in human plasma.